Celgene Corp (NASDAQ:CELG)

110.02
Delayed Data
As of 4:00pm ET
 -0.39 / -0.35%
Today’s Change
58.59
Today|||52-Week Range
110.70
+71.66%
Year-to-Date
Editas Expands Its Celgene Partnership After Another Strong Quarter
Nov 13 / MotleyFool.com - Paid Partner Content
Acceleron's Q3 Results Focus Squarely on Its Celgene Collaboration
Nov 06 / MotleyFool.com - Paid Partner Content
Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better
Nov 12 / MotleyFool.com - Paid Partner Content
Buy These 2 Stocks to Access China's Huge Healthcare Market
Nov 06 / MotleyFool.com - Paid Partner Content
Why Bristol-Myers Squibb Stock Gained 13% in October
Nov 11 / MotleyFool.com - Paid Partner Content
Here's Why Beigene Stock Is Soaring Today
Nov 01 / MotleyFool.com - Paid Partner Content
Better Buy: Biogen vs. Celgene
Nov 10 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close110.41
Today’s open109.95
Day’s range109.52 - 110.53
Volume4,150,528
Average volume (3 months)3,722,027
Market cap$77.9B
Data as of 4:00pm ET, 11/14/2019

Growth & Valuation

Earnings growth (last year)+49.83%
Earnings growth (this year)+24.82%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+19.26%
P/E ratio13.5
Price/Sales3.08
Price/Book12.44

Competitors

 Today’s
change
Today’s
% change
TAKTakeda Pharmaceutica...-0.02-0.10%
BMYBristol-Myers Squibb-0.28-0.48%
AGNAllergan+0.87+0.48%
----
Data as of 6:30pm ET, 11/14/2019

Financials

Next reporting dateJanuary 27, 2020
EPS forecast (this quarter)$2.80
Annual revenue (last year)$15.3B
Annual profit (last year)$4.0B
Net profit margin26.46%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Summit, New Jersey

Forecasts